{"entity":{"type":"insider","cik":"0001587074","url":"/insider/0001587074","json_url":"/insider/0001587074.json","name":"Trieu Vuong","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":30,"n_filings":21,"first":"2017-02-08","last":"2026-07-02","span_basis":"filed_date"},"name_variants":[{"name":"Trieu Vuong","source":"filing","n_filings":21,"first_seen":"2017-02-08","last_seen":"2026-07-02"}],"transactions":[{"id":5961141,"accession":"0001493152-26-031846","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-26-031846","line_url":"/filing/0001493152-26-031846#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":240000.0,"shares_display":"240,000","price_per_share":0.0431,"price_display":"0.04","price_state":"stated","total_value":10344.0,"total_display":"10,344.00","total_whole":"10,344","shares_owned_after":94124319.0,"shares_owned_after_display":"94,124,319","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-02","scope":"insider"},{"id":6148543,"accession":"0001493152-26-029997","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001493152-26-029997","line_url":"/filing/0001493152-26-029997#line-3","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":115000.0,"shares_display":"115,000","price_per_share":0.045,"price_display":"0.04","price_state":"stated","total_value":5175.0,"total_display":"5,175.00","total_whole":"5,175","shares_owned_after":93884319.0,"shares_owned_after_display":"93,884,319","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-24","filed_date":"2026-06-24","scope":"insider"},{"id":6148540,"accession":"0001493152-26-029997","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-26-029997","line_url":"/filing/0001493152-26-029997#line-2","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":75000.0,"shares_display":"75,000","price_per_share":0.045,"price_display":"0.04","price_state":"stated","total_value":3375.0,"total_display":"3,375.00","total_whole":"3,375","shares_owned_after":93769319.0,"shares_owned_after_display":"93,769,319","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-23","filed_date":"2026-06-24","scope":"insider"},{"id":6148537,"accession":"0001493152-26-029997","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-26-029997","line_url":"/filing/0001493152-26-029997#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":65000.0,"shares_display":"65,000","price_per_share":0.045,"price_display":"0.04","price_state":"stated","total_value":2925.0,"total_display":"2,925.00","total_whole":"2,925","shares_owned_after":93694319.0,"shares_owned_after_display":"93,694,319","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-22","filed_date":"2026-06-24","scope":"insider"},{"id":6212359,"accession":"0001493152-26-029137","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-26-029137","line_url":"/filing/0001493152-26-029137#line-2","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":239759.0,"shares_display":"239,759","price_per_share":0.0446,"price_display":"0.04","price_state":"stated","total_value":10693.2514,"total_display":"10,693.25","total_whole":"10,693","shares_owned_after":93629319.0,"shares_owned_after_display":"93,629,319","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-17","filed_date":"2026-06-17","scope":"insider"},{"id":6212356,"accession":"0001493152-26-029137","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-26-029137","line_url":"/filing/0001493152-26-029137#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":96000.0,"shares_display":"96,000","price_per_share":0.045,"price_display":"0.04","price_state":"stated","total_value":4320.0,"total_display":"4,320.00","total_whole":"4,320","shares_owned_after":93389560.0,"shares_owned_after_display":"93,389,560","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-15","filed_date":"2026-06-17","scope":"insider"},{"id":4276776,"accession":"0001641172-25-018620","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001641172-25-018620","line_url":"/filing/0001641172-25-018620#line-3","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":104000.0,"shares_display":"104,000","price_per_share":0.005,"price_display":"0.00","price_state":"stated","total_value":520.0,"total_display":"520.00","total_whole":"520","shares_owned_after":93293560.0,"shares_owned_after_display":"93,293,560","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-10","filed_date":"2025-07-10","scope":"insider"},{"id":4276774,"accession":"0001641172-25-018620","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001641172-25-018620","line_url":"/filing/0001641172-25-018620#line-2","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1.0,"shares_display":"1","price_per_share":0.005,"price_display":"0.00","price_state":"stated","total_value":0.005,"total_display":"0.00","total_whole":"0.00","shares_owned_after":93293561.0,"shares_owned_after_display":"93,293,561","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-09","filed_date":"2025-07-10","scope":"insider"},{"id":4276769,"accession":"0001641172-25-018620","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001641172-25-018620","line_url":"/filing/0001641172-25-018620#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":94736.0,"shares_display":"94,736","price_per_share":0.005,"price_display":"0.00","price_state":"stated","total_value":473.68,"total_display":"473.68","total_whole":"474","shares_owned_after":93388297.0,"shares_owned_after_display":"93,388,297","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-08","filed_date":"2025-07-10","scope":"insider"},{"id":4965325,"accession":"0001493152-25-004486","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001493152-25-004486","line_url":"/filing/0001493152-25-004486#line-3","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":63775.0,"shares_display":"63,775","price_per_share":0.028,"price_display":"0.03","price_state":"stated","total_value":1785.7,"total_display":"1,785.70","total_whole":"1,786","shares_owned_after":93189560.0,"shares_owned_after_display":"93,189,560","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-31","filed_date":"2025-01-31","scope":"insider"},{"id":4965321,"accession":"0001493152-25-004486","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-25-004486","line_url":"/filing/0001493152-25-004486#line-2","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100003.0,"shares_display":"100,003","price_per_share":0.028,"price_display":"0.03","price_state":"stated","total_value":2800.084,"total_display":"2,800.08","total_whole":"2,800","shares_owned_after":93125785.0,"shares_owned_after_display":"93,125,785","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-30","filed_date":"2025-01-31","scope":"insider"},{"id":4965314,"accession":"0001493152-25-004486","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-25-004486","line_url":"/filing/0001493152-25-004486#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":183066.0,"shares_display":"183,066","price_per_share":0.028,"price_display":"0.03","price_state":"stated","total_value":5125.848,"total_display":"5,125.85","total_whole":"5,126","shares_owned_after":93025782.0,"shares_owned_after_display":"93,025,782","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-29","filed_date":"2025-01-31","scope":"insider"},{"id":2425570,"accession":"0001493152-24-047762","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-24-047762","line_url":"/filing/0001493152-24-047762#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":298499.0,"shares_display":"298,499","price_per_share":0.0289,"price_display":"0.03","price_state":"stated","total_value":8626.6211,"total_display":"8,626.62","total_whole":"8,627","shares_owned_after":92842716.0,"shares_owned_after_display":"92,842,716","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-22","filed_date":"2024-11-26","scope":"insider"},{"id":2987794,"accession":"0001493152-24-033939","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-24-033939","line_url":"/filing/0001493152-24-033939#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":0.02,"price_display":"0.02","price_state":"stated","total_value":10000.0,"total_display":"10,000.00","total_whole":"10,000","shares_owned_after":92544217.0,"shares_owned_after_display":"92,544,217","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-23","filed_date":"2024-08-27","scope":"insider"},{"id":8712595,"accession":"0001493152-23-023015","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-23-023015","line_url":"/filing/0001493152-23-023015#line-2","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":425000.0,"shares_display":"425,000","price_per_share":0.021,"price_display":"0.02","price_state":"stated","total_value":8925.0,"total_display":"8,925.00","total_whole":"8,925","shares_owned_after":92044217.0,"shares_owned_after_display":"92,044,217","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-29","filed_date":"2023-06-30","scope":"insider"},{"id":8712591,"accession":"0001493152-23-023015","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-23-023015","line_url":"/filing/0001493152-23-023015#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":75000.0,"shares_display":"75,000","price_per_share":0.026,"price_display":"0.03","price_state":"stated","total_value":1950.0,"total_display":"1,950.00","total_whole":"1,950","shares_owned_after":91619217.0,"shares_owned_after_display":"91,619,217","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-28","filed_date":"2023-06-30","scope":"insider"},{"id":8746682,"accession":"0001493152-23-021800","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-23-021800","line_url":"/filing/0001493152-23-021800#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":0.026,"price_display":"0.03","price_state":"stated","total_value":2600.0,"total_display":"2,600.00","total_whole":"2,600","shares_owned_after":91544217.0,"shares_owned_after_display":"91,544,217","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-16","filed_date":"2023-06-20","scope":"insider"},{"id":8496845,"accession":"0001493152-23-021563","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-23-021563","line_url":"/filing/0001493152-23-021563#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":0.0326,"price_display":"0.03","price_state":"stated","total_value":13040.0,"total_display":"13,040.00","total_whole":"13,040","shares_owned_after":91444217.0,"shares_owned_after_display":"91,444,217","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-14","filed_date":"2023-06-16","scope":"insider"},{"id":8746650,"accession":"0001493152-23-019557","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-23-019557","line_url":"/filing/0001493152-23-019557#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":126888.0,"shares_display":"126,888","price_per_share":0.0341,"price_display":"0.03","price_state":"stated","total_value":4326.8808,"total_display":"4,326.88","total_whole":"4,327","shares_owned_after":91044217.0,"shares_owned_after_display":"91,044,217","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-26","filed_date":"2023-05-31","scope":"insider"},{"id":7942699,"accession":"0001493152-23-015195","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-23-015195","line_url":"/filing/0001493152-23-015195#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":0.045,"price_display":"0.04","price_state":"stated","total_value":4500.0,"total_display":"4,500.00","total_whole":"4,500","shares_owned_after":90917329.0,"shares_owned_after_display":"90,917,329","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-02","filed_date":"2023-05-02","scope":"insider"},{"id":6602214,"accession":"0001493152-22-034663","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-034663","line_url":"/filing/0001493152-22-034663#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":120000.0,"shares_display":"120,000","price_per_share":0.05,"price_display":"0.05","price_state":"stated","total_value":6000.0,"total_display":"6,000.00","total_whole":"6,000","shares_owned_after":90558021.0,"shares_owned_after_display":"90,558,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-06","filed_date":"2022-12-07","scope":"insider"},{"id":6685047,"accession":"0001493152-22-033681","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-033681","line_url":"/filing/0001493152-22-033681#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":70000.0,"shares_display":"70,000","price_per_share":0.08,"price_display":"0.08","price_state":"stated","total_value":5600.0,"total_display":"5,600.00","total_whole":"5,600","shares_owned_after":90438021.0,"shares_owned_after_display":"90,438,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-22","filed_date":"2022-11-25","scope":"insider"},{"id":6950074,"accession":"0001493152-22-026963","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-026963","line_url":"/filing/0001493152-22-026963#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":0.068,"price_display":"0.07","price_state":"stated","total_value":1360.0,"total_display":"1,360.00","total_whole":"1,360","shares_owned_after":90368021.0,"shares_owned_after_display":"90,368,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-26","filed_date":"2022-09-28","scope":"insider"},{"id":6602153,"accession":"0001493152-22-024234","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-024234","line_url":"/filing/0001493152-22-024234#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"Oncotelic Therapeutics, Inc.","issuer_ticker":"OTLC","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHAIRMAN AND CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":80000.0,"shares_display":"80,000","price_per_share":0.082,"price_display":"0.08","price_state":"stated","total_value":6560.0,"total_display":"6,560.00","total_whole":"6,560","shares_owned_after":90348021.0,"shares_owned_after_display":"90,348,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-25","filed_date":"2022-08-29","scope":"insider"},{"id":3149053,"accession":"0001493152-20-022256","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-20-022256","line_url":"/filing/0001493152-20-022256#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"MATEON THERAPEUTICS INC","issuer_ticker":"MATN","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF EXECUTIVE OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50500.0,"shares_display":"50,500","price_per_share":0.19,"price_display":"0.19","price_state":"stated","total_value":9595.0,"total_display":"9,595.00","total_whole":"9,595","shares_owned_after":15812308.0,"shares_owned_after_display":"15,812,308","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-19","filed_date":"2020-11-23","scope":"insider"},{"id":2262568,"accession":"0001415889-20-000880","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-20-000880","line_url":"/filing/0001415889-20-000880#line-1","is_derivative":false,"issuer_cik":"0000908259","issuer_name":"MATEON THERAPEUTICS INC","issuer_ticker":"MATN","issuer_name_source":null,"issuer_url":"/issuer/0000908259","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF EXECUTIVE OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":0.12,"price_display":"0.12","price_state":"stated","total_value":360.0,"total_display":"360.00","total_whole":"360","shares_owned_after":15761808.0,"shares_owned_after_display":"15,761,808","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-26","filed_date":"2020-03-27","scope":"insider"},{"id":4242625,"accession":"0001493152-17-006494","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-17-006494","line_url":"/filing/0001493152-17-006494#line-1","is_derivative":false,"issuer_cik":"0000737207","issuer_name":"Marina Biotech, Inc.","issuer_ticker":"MRNA","issuer_name_source":null,"issuer_url":"/issuer/0000737207","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman of the Board","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":0.39,"price_display":"0.39","price_state":"stated","total_value":3900.0,"total_display":"3,900.00","total_whole":"3,900","shares_owned_after":11127141.0,"shares_owned_after_display":"11,127,141","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-06-09","filed_date":"2017-06-12","scope":"insider"},{"id":4800744,"accession":"0001493152-17-006346","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-17-006346","line_url":"/filing/0001493152-17-006346#line-2","is_derivative":false,"issuer_cik":"0000737207","issuer_name":"Marina Biotech, Inc.","issuer_ticker":"MRNA","issuer_name_source":null,"issuer_url":"/issuer/0000737207","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman of the Board","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":0.39,"price_display":"0.39","price_state":"stated","total_value":7800.0,"total_display":"7,800.00","total_whole":"7,800","shares_owned_after":11117141.0,"shares_owned_after_display":"11,117,141","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-06-08","filed_date":"2017-06-08","scope":"insider"},{"id":4800738,"accession":"0001493152-17-006346","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-17-006346","line_url":"/filing/0001493152-17-006346#line-1","is_derivative":false,"issuer_cik":"0000737207","issuer_name":"Marina Biotech, Inc.","issuer_ticker":"MRNA","issuer_name_source":null,"issuer_url":"/issuer/0000737207","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman of the Board","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500.0,"shares_display":"2,500","price_per_share":0.38,"price_display":"0.38","price_state":"stated","total_value":950.0,"total_display":"950.00","total_whole":"950","shares_owned_after":11097141.0,"shares_owned_after_display":"11,097,141","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-06-07","filed_date":"2017-06-08","scope":"insider"},{"id":4292938,"accession":"0001493152-17-001242","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-17-001242","line_url":"/filing/0001493152-17-001242#line-1","is_derivative":false,"issuer_cik":"0000737207","issuer_name":"Marina Biotech, Inc.","issuer_ticker":"MRNA","issuer_name_source":null,"issuer_url":"/issuer/0000737207","owner_cik":"0001587074","owner_name":"Trieu Vuong","owner_display_name":"Trieu Vuong","owner_url":"/insider/0001587074","role":"Director, Officer (Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman of the Board","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":862068.0,"shares_display":"862,068","price_per_share":0.29,"price_display":"0.29","price_state":"stated","total_value":249999.72,"total_display":"249,999.72","total_whole":"250,000","shares_owned_after":862068.0,"shares_owned_after_display":"862,068","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-02-06","filed_date":"2017-02-08","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":30,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":30,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":30},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000908259","name":"Oncotelic Therapeutics, Inc.","url":"/issuer/0000908259","role":"Director, Officer (CHAIRMAN AND CEO), Ten percent owner","n_filings":18,"first_seen":"2020-03-27","last_seen":"2026-07-02"},{"type":"issuer","type_label":"ISSUER","cik":"0000737207","name":"Marina Biotech, Inc.","url":"/issuer/0000737207","role":"Director, Officer (Chairman of the Board), Ten percent owner","n_filings":3,"first_seen":"2017-02-08","last_seen":"2017-06-12"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001587074","retrieved_at":"2026-08-24T16:15:33+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}